Clinical Trial Update: Study of BGB-A317 in Participants With Previously Treated Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial of BGB-A317 in previously treated unresectable hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BGB-A317 (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: COMPLETED | Results posted: 2023-07-27